title: Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions.
abstract: A total of 249 client-owned dogs with osteoarthritis were treated with firocoxib (5 mg/kg/day) or a positive control, etodolac (10-15 mg/kg/day), for 30 days. Veterinary examinations were performed on approximately days 0 (visit 1), 14 (visit 2), and 29 (visit 3). Based on defined noninferiority criteria, firocoxib and etodolac were comparable. Based on the magnitude of the change from baseline, improvement with firocoxib was significantly greater than with etodolac for lameness at a trot (visits 2 and 3) and for lameness at a walk, pain on manipulation, and range of motion (visit 3) (P < .05). In weekly owner evaluations, firocoxib provided significantly greater improvement than etodolac (P < .05) at each scoring.
authors.affiliation: Merial Limited, 3239 Satellite Blvd, Duluth, GA 30096, USA.
authors.forename: Peter D
authors.initials: PD
authors.lastname: Hanson
authors.forename: Kenneth C
authors.initials: KC
authors.lastname: Brooks
authors.forename: Jerry
authors.initials: J
authors.lastname: Case
authors.forename: Michael
authors.initials: M
authors.lastname: Conzemius
authors.forename: Wanda
authors.initials: W
authors.lastname: Gordon
authors.forename: James
authors.initials: J
authors.lastname: Schuessler
authors.forename: Bert
authors.initials: B
authors.lastname: Shelley
authors.forename: Roger
authors.initials: R
authors.lastname: Sifferman
authors.forename: Marlene
authors.initials: M
authors.lastname: Drag
authors.forename: Roberto
authors.initials: R
authors.lastname: Alva
authors.forename: Laura
authors.initials: L
authors.lastname: Bell
authors.forename: Davida
authors.initials: D
authors.lastname: Romano
authors.forename: Candis
authors.initials: C
authors.lastname: Fleishman
mesh_terms: D015107:4-Butyrolactone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D017308:Etodolac / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D007794:Lameness, Animal / Q000188:drug therapy; D008297:Male; D010003:Osteoarthritis / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D016059:Range of Motion, Articular / Q000187:drug effects / Q000502:physiology; D012449:Safety; D013450:Sulfones / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D013450:Sulfones; D017308:Etodolac; D015107:4-Butyrolactone; C487384:firocoxib